clinical congestive heart failure occurred in 46 ( 16 percent ) during the treatment period , and in an additional three patients ( 1.3 percent ) at last follow-up examination 11.8 +/- 14.2 months following discontinuation of doxorubicin .
C0018802
congestive
C0013089
doxorubicin